Venetoclax is an anti-BCL2 agent approved in Europe for the treatment of chronic lymphocytic leukemia (CLL) that has shown therapeutic activity in mantle cell lymphoma (MCL) and other hematological malignancies (15–17). Here, BCL2 is linked to mantle cell lymphoma.